In fact, there are clinical trials on-going using modified autologous T-cells termed CARs.
These T-cells are transfected with chimeric molecules made of the variable region of an antibody that recognise a specific antigen expressed by the tumour (in this trail, the Ag is CD19 expressed by most lymphomas and certain leukaemia as CLL), fused to a signalling region of stimulatory molecules, either the zeta chain of CD3 or the intracellular domain of CD28.
For more deatials see Carl June and Michael Milone work on Pub-Med